All In Biotech

Free tool

FAERS Monitor: Levothyroxine Sodium

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 210632 or its brand name (Levothyroxine Sodium, Levothyroxine Sodium). Reports on generic versions are filed under their own applications.

Reports

101,616

Serious

70,416

69% of reports

Hospitalization

39,133

Death reported

8,379

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • fatigue8,321
  • nausea7,290
  • diarrhoea6,612
  • headache6,428
  • dyspnoea6,344
  • drug ineffective5,446
  • pain5,349
  • dizziness5,097
  • vomiting4,552
  • asthenia4,372
  • off label use4,143
  • fall4,135
  • malaise4,100
  • arthralgia3,999
  • pruritus3,495

Reports by year received

View as table
YearReports
20042,043
20052,018
20062,180
20072,759
20084,015
20093,823
20104,305
20116,146
20126,819
20131,402
20141,713
20152,374
20163,138
20173,608
20184,138
20194,005
20205,441
20215,804
20227,390
20236,974
20247,345
20258,275
20265,900

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,952,543 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
fallSignal4,1352.62.54,053
astheniaSignal4,3722.42.43,676
dyspnoeaSignal6,3442.32.34,917
fatigueSignal8,3212.22.25,766
headacheSignal6,4282.12.13,949
diarrhoeaSignal6,6122.12.14,056
dizzinessSignal5,0972.12.13,083
vomitingSignal4,5522.02.02,352
arthralgiaSignal3,9992.01.92,020
malaise4,1001.91.91,900
nausea7,2901.91.93,280
pruritus3,4951.91.81,479
pain5,3491.81.81,977
off label use4,1431.01.02
drug ineffective5,4460.90.8143

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.